Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes

Area of Science:

• Mitochondrial biochemistry
• Diabetes pathophysiology
• Cellular redox homeostasis

Background:

• NADH/NAD+ redox imbalance is a hallmark of diabetes, contributing to oxidative stress.
• Mitochondrial complex I is crucial for NADH oxidation, NAD+ regeneration, and reactive oxygen species (ROS) production.
• The response of pancreatic complex I to redox imbalance in diabetes and its consequences remain poorly understood.

Purpose of the Study:

• To investigate the behavior of pancreatic mitochondrial complex I in diabetes.
• To determine the impact of complex I hyperactivity on ROS production and beta cell function.
• To explore potential therapeutic strategies targeting complex I in diabetic pancreas.

Main Methods:

• Analysis of pancreatic mitochondrial complex I activity in streptozotocin (STZ)-induced diabetic models.
• Assessment of ROS production, mitochondrial membrane potential, and ATP production.
• Evaluation of cellular defense systems including glucose 6-phosphate dehydrogenase, sirtuin 3, and NQO1.

Main Results:

• Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in both type 1 and type 2 diabetes.
• Complex I hyperactivity is associated with increased ROS production, decreased mitochondrial ATP production, and impaired membrane potential.
• Metformin treatment attenuated complex I hyperactivity in STZ-induced diabetes.
• Cellular defense mechanisms were compromised in the diabetic pancreas.

Conclusions:

• Aberrant hyperactivity of pancreatic mitochondrial complex I is a significant source of oxidative stress and contributes to beta cell failure in diabetes.
• Inhibiting complex I hyperactivity and reducing its ROS production may represent a promising therapeutic avenue for diabetes treatment.